Nxera Pharma Regains Rights to Phase 2-Ready Schizophrenia Drug After Boehringer Ingelheim Declines Licensing Option
核心洞察
Boehringer Ingelheim declined to exercise its exclusive licensing option for Nxera Pharma (搜索)'s GPR52 agonist (搜索) program, including Phase 2-ready lead compound NXE0048149 for schizophrenia (搜索) treatment.
Phase 1 trials demonstrated NXE0048149's favorable safety profile with no severe adverse events and evidence of brain circuitry engagement relevant to treating all three symptom domains of schizophrenia (搜索).
Nxera plans to explore strategic partnerships with major pharmaceutical or neuroscience companies in 2026, as the schizophrenia (搜索) drug market is forecast to reach $12.9 billion by 2030.
Nxera Pharma (搜索) announced that Boehringer Ingelheim has decided not to exercise its exclusive option to license the company's GPR52 agonist (搜索) program for schizophrenia (搜索), including the Phase 2-ready lead compound NXE0048149. The decision returns full rights to the Japanese biotech company, which now plans to seek new strategic partnerships for the promising neuropsychiatric program.
Boehringer Ingelheim Withdraws from Collaboration
Boehringer Ingelheim informed Nxera of its decision without providing additional details regarding the rationale behind declining the licensing option. Under the terms of the original Collaboration and License Option Agreement, all rights to the GPR52 (搜索) portfolio will revert to Nxera Pharma (搜索), along with all data and intellectual property generated during the collaboration.
The original partnership, established in 2024 when Nxera was known as Sosei Group Corporation, included an upfront payment of €25 million to Nxera. The full agreement structure included an option exercise payment of €60 million, milestone payments totaling up to €670 million, and royalties for any approved products.
Market reaction was swift, with Nxera shares declining 5% to ¥817 ($5.19) at market open on December 19, compared to the previous day's close of ¥860. Citi analysts characterized Boehringer's decision as "negative" for Nxera, noting that "there had been expectations for this large-scale deal in 2025-2026."
Phase 1 Results Demonstrate Promising Profile
NXE0048149 and other GPR52 (搜索) agonists in the portfolio were developed using Nxera's NxWave™ structure-based drug design platform, specifically designed to address positive, negative, and cognitive symptoms of schizophrenia (搜索) simultaneously.
Phase 1 trial results revealed a highly favorable safety profile, with NXE0048149 well tolerated across all dose levels in healthy participants. The study reported no severe or serious adverse events and no adverse events leading to discontinuation. Pharmacokinetic analyses demonstrated dose-proportional exposure, equivalent free concentrations in plasma and cerebrospinal fluid at steady state, and a long half-life supporting once-daily dosing.
Notably, pharmacodynamic endpoints including cognitive assessments, neurophysiological measures, and peripheral biomarkers provided evidence of engagement of brain circuitry relevant to treating schizophrenia (搜索) and related disorders.
Addressing Unmet Medical Needs in Schizophrenia
The expression of GPR52 (搜索) in brain regions associated with different symptom domains of schizophrenia (搜索) positions NXE0148149 as a potentially transformative treatment option. Current therapies primarily address positive symptoms such as hallucinations and delusions, while leaving negative symptoms like social withdrawal and apathy, as well as cognitive dysfunction including attention and memory deficits, largely untreated.
Christopher Cargill, CEO and President of Nxera Pharma (搜索), commented: "Although we are disappointed that Boehringer Ingelheim has chosen not to proceed with the license option, its decision does not diminish the significant potential of the GPR52 agonist (搜索) program, which has demonstrated highly encouraging attributes as a first-in-class approach to treating several major symptoms of schizophrenia (搜索) and address the shortcomings of current treatment options."
Strategic Outlook and Market Opportunity
With the program now Phase 2-ready, Nxera plans to explore strategic opportunities, including a formal out-licensing process with the intention of partnering the program with a major pharmaceutical or specialist neuroscience company in 2026. The company emphasized that the event has no impact on its consolidated financial results for the current accounting period.
The timing coincides with significant growth in the schizophrenia (搜索) therapeutics market. According to GlobalData analysis, schizophrenia drug sales across the seven major markets are forecast to reach $12.9 billion by 2030. This growth trajectory was highlighted by Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies, the most expensive merger and acquisition deal of 2025, which brought the schizophrenia drug Caplyta into J&J's portfolio.
Cargill added: "We are energised by the strong scientific and clinical foundations already established and see meaningful opportunity in regaining full rights. We look forward to updating the market as we advance discussions with potential partners next year."
The development occurs during a challenging period for Nxera, which announced plans in November 2025 to cut 15% of its workforce and reprioritize its pipeline to pursue profitability targets, with increased focus on therapies for obesity, metabolic and endocrine disorders.